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Introduction
Barrett’s esophagus (BO) is a change in the cells of esophageal
tissue and a precursor to esophageal cancer. BO carries a risk of
cancer 30 to 150 times greater than that for an age-matched
population without BO, and affects 375,000 people in the UK
[1, 2]. Esophageal cancer is the fifth most common cancer in
the UK and carries a poor 5-year survival rate of < 5% [3, 4]. Cur-
rent guidelines recommend regular surveillance (between 2–5
years according to length of Barrett’s) to detect and remove
early dysplasia, [5] as patients diagnosed with esophageal can-
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ABSTRACT
Background and study aims Barrett’s esophagus is a po-
tentially pre-cancerous condition, affecting 375,000 people
in the UK. Patients receive a 2-yearly endoscopy to detect
cancerous changes, as early detection and treatment re-
sults in better outcomes. Current treatment requires ran-
dom mapping biopsies along the length of Barrett’s, in ad-
dition to biopsy of visible abnormalities. As only 13% of pre-
cancerous changes appear as visible nodules or abnormal-
ities, areas of dysplasia are often missed. Acetic acid chro-
moendoscopy (AAC) has been shown to improve detection
of pre-cancerous and cancerous tissue in observational
studies, but no randomized controlled trials (RCTs) have
been performed to date.
Patients and methods A “tandem” endoscopy cross-over
design. Participants will be randomized to endoscopy using
mapping biopsies or AAC, in which dilute acetic acid is
sprayed onto the surface of the esophagus, highlighting tis-
sue through an whitening reaction and enhancing visibility
of areas with cellular changes for biopsy. After 4 to 10
weeks, participants will undergo a repeat endoscopy, using
the second method. Rates of recruitment and retention will
be assessed, in addition to the estimated dysplasia detec-
tion rate, effectiveness of the endoscopist training pro-
gram, and rates of adverse events (AEs). Qualitative inter-
views will explore participant and endoscopist acceptability
of study design and delivery, and the acceptability of
switching endoscopic techniques for Barrett's surveillance.
Results Endoscopists’ ability to diagnose dysplasia in Bar-
rett’s esophagus can be improved. AAC may offer a simple,
universally applicable, easily-acquired technique to improve
detection, affording patients earlier diagnosis and treat-
ment, reducing endoscopy time and pathology costs. The
ABBA study will determine whether a crossover “tandem”
endoscopy design is feasible and acceptable to patients
and clinicians and gather outcome data to power a defini-
tive trial.
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cer within a surveillance program have earlier-stage disease and
longer survival times [6, 7].
The current gold-standard technique for detecting dysplasia
in surveillance programs involves quadrantic esophageal biop-
sies every 2 cm during endoscopy (Seattle protocol). This is
necessary as only 13% of dysplastic changes appear as visible
nodules [8]. However, up to 40% of early cancers are missed,
as despite multiple biopsies, only a small proportion of the total
surface area of the esophagus is sampled [9]. In practice, only
50% of surveillance endoscopies are estimated to adhere to
this method as it is laborious and time-consuming, poorly toler-
ated by patients, and expensive to process biopsies [10]. Re-
search to improve surveillance effectiveness and test perform-
ance has been recognized as a priority [11].
Currently, the key limitation to Barrett’s surveillance is the
macroscopic invisibility of Barrett’s dysplasia. Methods pro-
posed to enhance dysplasia visibility, thus permitting targeted
biopsies, include dye sprays, [12–14] electronic image intensi-
fiers built into the endoscope namely: narrow band Imaging,
[15] Fujinon intelligent color enhancement [16] and autofluor-
escence imaging [17]. However, evidence focuses on high-risk
populations where dysplasia has already been identified, or in
the follow-up of patients treated endoscopically for dysplasia.
It is lacking in a surveillance population, where dysplasia preval-
ence is significantly lower.
When sprayed on Barrett’s mucosa, acetic acid (AA) high-
lights specific surface patterns including dysplasia and cancer,
which can be readily recognized by the trained endoscopist
[18]. After application of AA, dysplastic tissue appears red
against the surrounding Barrett’s making it easily visible
(▶Fig. 1) [19]. This process is reversible, causes no damage to
tissues and can be repeated. Two large cohort studies have
demonstrated the efficacy of AA for detection of Barrett’s dys-
plasia in a high-risk population, reporting sensitivities of 90% to
95% and specificities of 75% to 85% [20, 21]. Further research
suggested that the number of biopsies could be substantially
reduced using AA-targeted biopsies instead of quadrantic biop-
sies, reducing pathology costs by 97% [22]. A recent retrospec-
tive study suggested that the AA method may detect more dys-
plasia than protocol-guided biopsies in a Barrett’s surveillance
population; 4.3% vs 1.4%, however, that study had a number
of limitations in that it did not control for endoscopist, was ret-
rospective and liable to confounding [23].
The 2 methods need to be compared in an RCT. However,
prior to a definitive study, a feasibility study is required to es-
tablish whether a cross-over design involving 2 endoscopies
per participant is acceptable, by assessing recruitment and re-
tention rates and exploration through qualitative interviews. It
is also important to ascertain the efficacy of training clinicians
to use the technique, and their perceptions of a change in the
endoscopic method. Estimates of diagnostic accuracy for both
groups are required to power a definitive trial.
Patients and methods
Research question
Is a trial to investigate the diagnostic accuracy of AAC in a Bar-
rett’s surveillance population feasible and acceptable to pa-
tients and endoscopists?
Objectives
This feasibility study will investigate: (1) the outcomes of a no-
vel training program for AA-guided dysplasia detection for
endoscopists; (2) feasibility of recruiting 200 Barrettʼs surveil-
lance patients in 18 months; (3) eligibility rate of screened pa-
tients; (4) recruitment rate of eligible patients; (5) the rate of
attendance for second endoscopy (retention rate) and reasons
for non-attendance; (6) participant acceptability of the study
design and acceptability of a change in surveillance technique;
(7) the difference in dysplasia detection rates between AA
endoscopy and standard endoscopic practice to inform the
▶ Fig.1 a Barrettʼs neoplasia seen in white light. b Same area after
acetic acid dye-spray – note early loss of acetowhitening.
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power calculation for a definitive study; (8) AE types and fre-
quencies; and (9) perceptions, values and opinions of endos-
copists of changing surveillance technique in practice.
Design
A mixed-methods feasibility study will be conducted with 3
components: (1) training and assessment of endoscopists in
the AA (intervention) and Seattle biopsy (current standard)
technique; (2) multicenter randomized, cross-over tandem
endoscopy trial examining diagnostic accuracy of 2 methods
of detecting cellular changes in patients with BO; and (3) tele-
phone interviews to gather qualitative data from patients and
endoscopists regarding study design and acceptability of im-
plementation of the AA technique as standard care.
Endoscopist training
1. Validation of image and video library: Images and videos of
AA chromoendoscopy in normal and dysplastic Barrett’s va-
lidated by 2 international expert endoscopists will form a
training and assessment library. The accuracy and inter-ob-
server agreement between experts will be calculated and
used to set the pass mark for the assessment tool.
2. Web-based training and assessment: The web-based train-
ing tool will be developed to provide a robust model suitable
for training endoscopists for the definitive trial. Baseline
knowledge will be assessed, followed by a tutorial of images
and videos from the library to demonstrate the AA appear-
ances of normal, dysplastic and cancerous Barrett’s, includ-
ing the Portsmouth AA classification. A series of practice
questions for a diagnosis (normal or dysplastic Barrett’s) will
be administered. Endoscopist trainees will be given im-
mediate feedback including a detailed description of what
was in the image or video to facilitate improved knowledge.
3. Face- to-face training: All endoscopists will attend an inter-
active workshop, including lecture-based training and inter-
active discussion with experts, followed by observing live
procedures over a video-link. Trainees will then repeat the
assessment tool. Once endoscopists achieve adequate ac-
curacy scores, defined as achieving scores within 5% of ex-
perts, they will perform an endoscopy list under the direct
supervision of an expert in AA at their own institutions.
Participants
Participants will be recruited from 6 centers in the UK, i. e.
Portsmouth, Leicester, Gloucestershire, Western Sussex,
Brighton and Sussex, and Royal Bournemouth and Christchurch
trusts. The study design summarized in ▶Fig. 2 and ▶Fig. 3
demonstrates the schedule of enrollment, interventions and
assessments. Recruitment commenced in July 2015 at Ports-
mouth Hospitals NHS Trust, the lead trial site.
Enrollment
Interested 
participants sent PIS 
and meet with 
research team
1st Gastroscopy
2nd Gastroscopy
Qualitative study
▪ Patients undergoing surveillance for Barrett's oesophagus contacted for routine screening
 appointment with additional written invitation to join the study 4–6 weeks before surveillance 
 due to discuss entry into the study.
▪ These patients will be entered onto a screening log.
▪ Follow up phone call from research team within 7 days.
▪ Rarely contact can be made at shorter notice provided a patient information sheet can be issued in 
 enough time for the patient to be able to read and consider the issues involved (> 24 hours).
▪ Patients interested in taking part in the study are allocated to a research list and invited to attend 
 30 minutes prior to gastroscopy to meet with member of research team, when consent will be
 taken, the 1st part of the CRF will be completed and patient will be randomized.
▪ Consent can be withdrawn at any time.
▪ Patients declining to take part at this point will be offered a standard gastroscopy.
▪ Reason for decline entered into screening log.
▪ If patients do not attend second gastroscopy a protocol deviation form will be completed. Patients
 will be contacted and asked for reasons for non-attendance.
▪ Patients simply missing their appointment and wishing to continue the study will be reappointed.
▪ Patients wishing to withdraw from the study are able to do so but will be offered the opportunity
 to remain in the study data for purposes of intention to treat analysis and for the qualitative
 interview study.
▪ A percentage of patients (maximum 40) will be contacted by the qualitative research team to
 complete a telephone questionnaire regarding experience of tandem endoscopy and perceptions
 of acetic acid chromoendoscopy.
▶ Fig. 2 Study design for participants.
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Eligibility criteria
Inclusion criteria
1. aged 18 years or above
2. biopsy (histologically) proven Barrett’s metaplasia
3. at least 2-cm length of Barrett’s esophagus
4. informed consent
Exclusion criteria
1. significant oesophagitis
2. known or prior esophageal cancer or esophageal dysplasia
3. previous endoscopic therapy for dysplasia
4. known allergy to acetic acid
5. previous inclusion in the study
Recruitment
Cross-over tandem endoscopy study
Patients scheduled to attend surveillance gastroscopy endos-
copy will receive a letter 4 to 6 weeks before the visit, followed
by a letter of invitation and patient information sheet for inter-
ested individuals.
Thirty minutes prior to gastroscopy, potential participants
will discuss the study with the research team and provide in-
formed consent.
Qualitative interviews
Patients
For qualitative data collection, a probabilistic sample size calcu-
lation was not appropriate. Instead, a purposive sampling fra-
mework to include male and female participants of all ages,
and across the study sites will be selected for interview. Data
collection will cease when saturation of data has been achieved
Timeline (months) 1–3 4–6 7–12 13–15 16–18 19–21 22–24 25–27 28–31
Study set up
Trial co-ordinator established in post
Sponsor checks and research & ethical approval secured 
Trial management group and trial steering group convened
NIHR portfolio form submitted
Site feasibility and capacity assessments
R&D submission and approval obtained for all sites
Training of study endoscopists
Image and video based training tools developed
Dates for training days ﬁ nalised and study endoscopists invited to attend
Training of the study endoscopists for cross-over study
Assessment of study endoscopists prior to commencing cross-over study
Qualitative assessment of conﬁ dence/attitudes of study endoscopists
Randomized cross-over diagnostic study
Patient invitation and recruitment begins
All sites recruiting
Recruitment
Quarterly meeting of the trial steering commitee
Monthly meeting of the trial management group
Complete recruitment into cross-over study
Closure of cross-over study
Qualitative patient and clinician study
Invitation
Scheduling of telephone interviews
Telephone interviews
Complete recruitment into qualitative study
Study closure
Analysis of data
Quantitative cross-over study data analysis
Qualitative study data analysis
Dissemination and publication of data
Dissemination of data at conferences and through patient groups
Publication of data in research journals
▶ Fig. 3 Study timeline.
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or no new insights are forthcoming. In this way, we will be con-
fident that the data will truly reflect the views and perspectives
of the range of study participants
On enrollment into the endoscopy study, participants will be
asked whether they would consent to being contacted to take
part in a telephone interview up to 4 weeks after the endosco-
pies are completed, and written information will be given to
them. Patients who do not wish to take part in the endoscopy
study will be asked for their consent to be interviewed about
their experience of hearing about the study and why they deci-
ded not to participate.
Endoscopists
Prior to the endoscopy training program, endoscopists will be
asked to take part in telephone interviews at the completion of
the trial (minimum of 8 interviews).
Randomization and blinding
Participants will be randomized using permuted blocks, strati-
fied by center in a 1:1 ratio, to initial endoscopy of either the
standard procedure (Seattle protocol mapping biopsies) or AA
endoscopy (targeted biopsies). The secure randomization web-
site, https://www.sealedenvelope.com will be used. Patients
will be unable to detect whether acetic acid had been used
and thus will be blinded to the procedure method. The endos-
copist will be blinded to the histological results of the previous
endoscopy for an individual participant. It will not be possible
to blind the histopathologist as the Seattle protocol produces
a greater number of biopsies for processing.
Study intervention
Study participants will receive an endoscopy using both meth-
ods, at an interval of 4 to 10 weeks, with the initial endoscopy
method determined by randomization allocation. The endosco-
pies will be performed with high-definition processors (Olym-
pus Lucera Elite or Spectrum and Pentax EPKi7000) and high-
definition gastroscopes (Olympus HQ290 or H260 and Pentax
i10 series) without use of electronic chromoendoscopy or alter-
native dye sprays. All study endoscopies will be videoed and
10% of non-dysplastic cases reviewed by the study team, in ad-
dition to all cases of dysplasia.
Acetic acid method
Following a pre-endoscopy mucosal cleansing drink, the Bar-
rett’s segment will be inspected using standard white light
and visible abnormalities noted. A spray catheter will be inser-
ted through the biopsy channel of the endoscope and AA 2.5%
sprayed onto the Barrett’s mucosa. Excess fluid will be removed
and mucosa inspected for abnormalities, which will be biop-
sied. Each biopsy will be sent to the laboratory in an individual
cassette. Areas for biopsy will be identified using the Ports-
mouth Barrett’s Acetic Acid Classification (PREDICT Classifica-
tion) [24], and the tissue will be categorized into non-dysplas-
tic, dysplastic or cancer. If no visible neoplasia is seen, no biop-
sies will be taken.
Control method
The control arm involves a standard gastroscopy according to
the Seattle protocol of quadrantic biopsies taken every 2 cm,
in addition to biopsies from any visible abnormalities.
Histological methods
Biopsies will be analyzed and reported by accredited NHS hospi-
tal laboratories at each site according to clinical pathology ac-
creditation (CPA) ISO 15189 quality control procedures. Speci-
mens where a histological diagnosis of dysplasia is suspected
will be examined by 2 expert gastrointestinal pathologists, and
a third opinion will be sought in case of disagreement.
Measurement of outcomes
Training assessment
Sensitivity, specificity, positive predictive value and negative
predictive value will be calculated for all image and video as-
sessments performed by the endoscopists. Kappa scores will
be used to assess interobserver agreement. Endoscopists will
be asked how confident they would be to switch practice at
each stage of the training process (pre-online training, post-on-
line training, post-training day). Following training, they will be
asked what the components of an AA training program should
be.
Study process
Information will be gathered from trial documentation, includ-
ing numbers of patients recorded on screening logs, consent
logs and withdrawal forms (e. g. detection of cancer on first
endoscopy or patient-led withdrawal prior to second endos-
copy).
Endoscopic and histology outcomes
Endoscopy process outcomes include duration of endoscopy,
use of sedation and level of patient discomfort using a 10-point
scale (1 =no discomfort, 10 = severe discomfort). Diagnostic
outcomes include the length of Barrett’s observed, islands of
Barrett’s reported according to the Prague criteria, presence
of endoscopically visible inflammation, visible abnormalities re-
quiring targeted biopsies (recorded as per Paris classification
and Prague criteria), number of biopsies performed, and endo-
scopic diagnosis (metaplasia, dysplasia or cancer) [25, 26]. Dys-
plasia will be categorized as low- or high-grade [5].
Study visit schedule
Baseline information includes: demographics, educational
achievement and occupation, lifestyle (smoking, alcohol), his-
tory of Barrett’s (date of first diagnosis, previous histology),
current medications (including aspirin, clopidogrel, non-steroi-
dal anti-inflammatory medicines, proton-pump inhibitors) and
significant medical history.
The first endoscopy will be performed, followed by a second
endoscopy after a 6-week interval (–2/+4 week window), per-
mitting the esophagus to heal.
During endoscopy, data will be collected concerning seda-
tion (dose and type administered), procedure duration, charac-
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teristics of Barrett’s, number of biopsies and patient discom-
fort. Histology results from both endoscopies will be released
as per standard care as soon as possible after the second endos-
copy has been completed.
Safety reporting
AEs will be collected during the procedure and in the following
24 hours. Data collected include a description of the event,
date/time of onset, intensity, relatedness to the procedure,
whether the event was categorized as a serious adverse event
(SAE), action taken, date of resolution (if resolved) and final
outcome of the event [27].
Sample size
Based on the historical cohort studies and wide consultation
within the British Society of Gastroenterology research com-
mittee and consultation with experts in the field, it was estima-
ted that 200 patients would be reasonable for recruitment to
enable the reproducibility and generalizability of the data to
be established. The purpose of this study is not to produce sta-
tistically significant data in itself but to establish likely event
rates and effect size to inform the power calculation for the de-
finitive study. Within the target sample size of 200 patients, the
intention is to recruit at least 30 patients per site over 6 centers.
Data management
Data will be managed by the Gloucester Clinical Trials Unit
(GCTU), using a Structured Query Language database (Trans-
act-SQL 2008, Microsoft, USA), including an electronic audit
trail.
Statistical analysis
The study will be reported in accordance with the Consolidated
Standards of Reporting Trials statement and ICH Guidelines for
Good Clinical Practice.
There are no planned interim analyses. All participants will
be included in analysis. Participants who do not attend the sec-
ond endoscopy will have their first endoscopy data included
with analysis of the appropriate treatment group.Analyses will
be performed using Stata (College Station, Texas). As this is a
feasibility study and was not powered to be able to test for dif-
ferences between the 2 endoscopy methods, formal statistical
testing is not appropriate. Descriptive statistics will be used for
each arm in order to inform a further definitive trial. The pro-
portion of patients not attending the second endoscopy will
be calculated, and for purposes of the feasibility analysis, the
results of the endoscopy will be included in the descriptive sta-
tistics for each group. This will allow collection of preliminary
data to inform the sample size calculation for a definitive trial,
and therefore, all data collected will be included to provide bet-
ter information.
Study process indicators
These include: (1) total participant recruitment, by site and
month of study; (2) screening success rate (eligible patients/
patients screened); (3) consent rate (patients recruited/eligible
patients); (4) rate of attendance to first and second endosco-
pies; and (5) rate of withdrawal from study, and reasons where
provided.
Neoplasia yield
Rates of dysplasia detection, (endoscopies with dysplasia/total
endoscopies), will be calculated for both methods of endos-
copy. True histology is defined as the combination of results
from both endoscopies (targeted+mapping biopsies). The dys-
plasia detection rate for each technique is defined as patients
with biopsy confirmed dysplasia by each technique/total pa-
tients with dysplasia.
Additional endoscopy outcomes
These will be presented according to the endoscopy technique.
Descriptive statistics (proportions, means, standard deviations,
confidence intervals) will describe the following: duration of
gastroscopy; use of sedation; endoscopic diagnosis (metapla-
sia, dysplasia or cancer); Barrett’s length; presence of Barrett’s
islands; visible abnormalities leading to targeted biopsies dur-
ing all procedures and total number of biopsies; suspected di-
agnosis (metaplasia, dysplasia); patient discomfort (10-point
scale).
Safety
The frequency and severity of AEs of interest, grouped by type,
namely chest infection/aspiration, bleeding and other compli-
cations considered to be related to the procedure will be re-
ported.
Qualitative methods
Patient participants: an introductory letter, contact details and
a photograph of the lead qualitative researcher will be provided
prior to the telephone interview. Informed consent will be tak-
en prior to the interview. Telephone interviews will take place a
minimum of 2 days, but no longer than a month after the end
of study participation and last approximately 30 minutes. To-
pics include experiences of study participation, views of the im-
pact for patients if the AA technique became standard practice,
and facilitators and barriers to recruitment and retention for a
definitive trial. Following the interview, brief field notes will be
taken to record any immediate reflections and emerging
themes.
Endoscopist participants: At least 8 endoscopists who had
participated in delivering the ABBA trial will be recruited to
take part in telephone interviews at the completion of the trial.
Topics for the interview include concerns regarding the proce-
dure prior to training, experience of training, perception of use-
fulness and suitability of the AA technique and feasibility study
methods for the definitive trial.
Data analysis
Participants will be identified by a unique number in the data-
base and audio recordings. Audio recordings will be transcribed
and entered into NVivo 10 (QSR International, Melbourne, Aus-
tralia).
Data will be analyzed through a process of thematic analysis
using the Framework approach. Categories will be independ-
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ently coded by 2 researchers, and a member of the steering
group will read a sample of transcripts to generate a prelimin-
ary framework without knowledge of the original researchers’
list. In case of disagreement, a solution will be sought to clarify
the meaning of a code/theme developed. A deductive approach
to map themes from the 2 groups of participants (patients and
endoscopists) will enable us to compare and contrast similari-
ties and differences of attitudes, perceptions and experience.
Public patient involvement
Patients, carers and the public from Heartburn Cancer UK and
the University of Portsmouth School of Health Sciences and So-
cial Work ENGAGE group were involved in the grant application,
study design including interview schedules, and will be involved
in study delivery.
Ethics
Favorable ethical approval for this study was given by the Na-
tional Research Ethics Service (NRES) Committee, South Cen-
tral–Berkshire, reference 15/SC/0085.
Because the study involves 2 endoscopies, participants will
be exposed to the risk of experiencing endoscopy-related AEs
twice. However, the overall risk of such events is very small,
and the benefit:risk of having 2 methods of detecting potential
dysplasia may outweigh the small increased risk of AEs. Second-
ly, there is a delay of a maximum of 6 weeks for histology to be-
come available due to the requirement for blinding of the sec-
ond endoscopy. However, in the case that cancer is detected
during either endoscopy, samples will be prioritized, immediate
referral for treatment made, and the participant withdrawn so
as not to delay treatment.
Funding
The ABBA study is funded by National Institute of Health Re-
search (NIHR) Research for Patient Benefit (RFPB) program
(Project Number PB-PG-1013-32045).
Dissemination
The results of this feasibility study will be disseminated to all
groups who are able to offer input and suggestions for further
work, i. e. patients with Barrett’s and patient support groups,
gastroenterologists, pathologists, and those involved in mana-
ging the workflow for the Barrett’s surveillance program within
the British Society of Gastroenterology (BSG).
Discussion
The ABBA feasibility study is the first randomized cross-over
trial exploring the use of acetic acid chromoendoscopy (AAC)
in a Barrett’s surveillance population. It has been designed to
provide comprehensive quantitative and qualitative data to in-
form and power a definitive, multicenter RCT. It will clarify
whether a crossover tandem endoscopy design is a feasible ap-
proach for this study for patients and endoscopists, or whether
a larger trial would require a parallel design.
When introducing any new technique into mainstream clini-
cal practice it is vital that we understand how to train clinicians
to perform the technique safely. This has been lacking in the in-
troduction of other endoscopic techniques, e. g. indigocarmine
chromoendoscopy in ulcerative colitis surveillance or colonic
polyp in vivo diagnosis, where efficacy has been demonstrated
by experts, but with no consideration of how to train all practi-
cing endoscopists on the technique [28, 29]. Evidence from in
vivo diagnosis studies of colonic polyps showed results obtain-
ed in expert hands can be very different to those obtained in a
general hospital, [30] and therefore development and assess-
ment of appropriate training is a key element of this study.
This activity also promotes cross-working of endoscopists
across units, and enables up-skilling as well as skill-sharing
which will benefit endoscopists normal practice. It also grows
and strengthens the existing network of clinicians with an inter-
est in Barrett’s research, and contributes to timely delivery of
trials in this area, to maximise patient benefit.
The use of qualitative methods to examine patient and clin-
ician barriers and facilitators to the adoption of AAC is essential
to inform future pathways to implementation. Health care
should be patient-centered. If a change in practice is to be re-
commended, it is important we understand the best way of
making these changes, and the best way of presenting informa-
tion on new techniques to patients to reduce potential anxiety
and to reassure patients that they are still receiving the best
care.
Finally, we would like to highlight the essential role of the
Public Patient contributors in providing feedback throughout
study development and delivery, and working within the re-
search team to ensure the patient-facing aspects of the study
are kept pragmatic and appropriate for patients.
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